Cargando…
Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA
Background. Previous research focused on the clinical evidence supporting new cancer drugs’ initial US Food and Drug Administration (FDA) approval. However, targeted drugs are increasingly approved for supplementary indications of unknown evidence and benefit. Objectives. To examine the clinical tri...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Springer US
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9288371/ https://www.ncbi.nlm.nih.gov/pubmed/35389145 http://dx.doi.org/10.1007/s10637-022-01227-5 |